MDGN
MedgenicsNYSEMKT
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Dec. 6, 3:46 PM
    • Uber bull H.C. Wainwright initiates coverage of Medgenics (MDGN +4.8%) with a Buy recommendation and $14 (164% upside) price target.
    • The gene therapy company's lead product candidate is NFC-1, in Phase 2/3 development for children and adolescents with attention deficit hyperactivity disorder who have a particular genetic profile.
    | Tue, Dec. 6, 3:46 PM
  • Thu, Nov. 3, 8:02 AM
    | Thu, Nov. 3, 8:02 AM
  • Tue, Oct. 11, 6:42 AM
    • Effective October 21, Medgenics (NYSEMKT:MDGN) will be listed on the Nasdaq Global Market under its current symbol. It will continue trading on the NYSE Amex until then.
    | Tue, Oct. 11, 6:42 AM
  • Thu, Aug. 4, 8:03 AM
    • Medgenics (NYSEMKT:MDGN): Q2 EPS of -$0.35 misses by $0.05.
    • Cash and cash equivalents of $53.7M.
    • Press Release
    | Thu, Aug. 4, 8:03 AM
  • Tue, Jun. 21, 12:48 PM
    | Tue, Jun. 21, 12:48 PM | 12 Comments
  • Tue, Jun. 21, 11:00 AM
    | Tue, Jun. 21, 11:00 AM | 1 Comment
  • Tue, Jun. 21, 9:12 AM
    | Tue, Jun. 21, 9:12 AM
  • Fri, Jun. 17, 8:36 AM
    • Gene therapy firm Medgenics (NYSEMKT:MDGN) has enrolled the first patient in its Phase 2/3 clinical trial, SAGA, assessing lead product candidate NFC-1 in adolescent patients with attention deficit hyperactivity disorder (ADHD).
    • The double-blind, placebo-controlled study will recruit 90 ADHD patients between the ages of 12 and 17 years who have genetic disorders impacting the mGluR (metabotropic glutamate receptor) network. Participants will be randomized 1:1 to receive either a six-week course of NFC-1 or placebo, with a one-week follow-up. The primary endpoint is the change from baseline in the ADHD-rating scale (ADHD-RS-5) Total Score to Visit 8 (Week 6). According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is October. The estimated study completion date is November.
    • Small molecule NFC-1 is an mGluR modulator that is based on a technology called Transduced Autologous Restorative Gene Therapy ((TARGT)). According to the company, TARGT enables greater cell uptake, less immunogenicity, improved safety and tolerability and lower cost than other gene therapies.
    • MGluRs are a family of protein receptors that bind to glutamate, an amino acid that plays a key role in neurotransmission. Manipulating mGluRs is being investigated for the potential treatment of certain cancers, Parkinson's disease, anxiety disorders, autism and schizophrenia.
    | Fri, Jun. 17, 8:36 AM
  • Tue, May 10, 8:15 AM
    • Medgenics (NYSEMKT:MDGN): Q1 EPS of -$0.34 misses by $0.08.
    • Cash and cash equivalents of $43.9M.
    | Tue, May 10, 8:15 AM
  • Wed, Feb. 17, 9:54 AM
    • Medgenics (MDGN +5.8%) Q4 results: Revenues: $0; R&D Expense: $4.3M (+13.2%); SG&A: $2.1M (-12.5%); Net Loss: ($6.5M) (-4.8%); Loss Per Share: ($0.20) (+33.3%).
    • FY2015 results: Revenues: $0; R&D Expense: $15.4M (+85.5%); SG&A: $13M (+21.5%); Operating Loss: ($36.6M) (-93.7%); Net Loss: ($38M) (-106.5%); Loss Per Share: ($1.55) (-55.0%); Quick Assets: $33.3M (-37.3%).
    • No guidance given.
    | Wed, Feb. 17, 9:54 AM
  • Wed, Feb. 17, 8:04 AM
    • Medgenics (NYSEMKT:MDGN): Q4 EPS of -$0.20 beats by $0.08.
    | Wed, Feb. 17, 8:04 AM
  • Oct. 22, 2015, 10:34 AM
    • Medgenics (MDGN -0.3%) Q3 results: Revenues: $0; R&D Expense: $4.2M (+162.5%); SG&A: $3M (+30.4%); Operating Loss: ($15.4M) (-294.9%); Net Loss: ($16.5M) (-450.0%); Loss Per Share: ($0.66) (-214.3%); Quick Assets: $17.7M (-46.8%).
    • No guidance given.
    | Oct. 22, 2015, 10:34 AM
  • Oct. 22, 2015, 8:05 AM
    • Medgenics (NYSEMKT:MDGN): Q3 EPS of -$0.66
    | Oct. 22, 2015, 8:05 AM
  • Oct. 7, 2015, 6:57 PM
    • Medgenics (NYSEMKT:MDGN) commences a public of common stock. Price, volume and terms have yet to be announced.
    • Shares are unchanged in after hours trading.
    | Oct. 7, 2015, 6:57 PM
  • Oct. 1, 2015, 12:40 PM
    | Oct. 1, 2015, 12:40 PM | 1 Comment
  • Oct. 1, 2015, 9:00 AM
    • Medgenics (NYSEMKT:MDGN) is down 14% premarket on light volume in response to its announcement of a public offering of common stock. Price, volume and terms have yet to be announced.
    | Oct. 1, 2015, 9:00 AM